JP2005502314A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005502314A5 JP2005502314A5 JP2002570736A JP2002570736A JP2005502314A5 JP 2005502314 A5 JP2005502314 A5 JP 2005502314A5 JP 2002570736 A JP2002570736 A JP 2002570736A JP 2002570736 A JP2002570736 A JP 2002570736A JP 2005502314 A5 JP2005502314 A5 JP 2005502314A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- human
- sequence
- self
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims 30
- 108090000623 proteins and genes Proteins 0.000 claims 30
- 102000003839 Human Proteins Human genes 0.000 claims 18
- 108090000144 Human Proteins Proteins 0.000 claims 18
- 210000003719 b-lymphocyte Anatomy 0.000 claims 13
- 229960005486 vaccine Drugs 0.000 claims 12
- 230000028993 immune response Effects 0.000 claims 10
- 238000006467 substitution reaction Methods 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 8
- 241000894007 species Species 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 claims 5
- 102000019207 human interleukin-13 Human genes 0.000 claims 5
- 230000006058 immune tolerance Effects 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 108090000176 Interleukin-13 Proteins 0.000 claims 4
- 102000003816 Interleukin-13 Human genes 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 3
- 230000004962 physiological condition Effects 0.000 claims 3
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 230000005875 antibody response Effects 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 102000008300 Mutant Proteins Human genes 0.000 claims 1
- 108010021466 Mutant Proteins Proteins 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940023143 protein vaccine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0105360.2A GB0105360D0 (en) | 2001-03-03 | 2001-03-03 | Chimaeric immunogens |
| PCT/GB2002/000900 WO2002070711A1 (en) | 2001-03-03 | 2002-03-01 | Vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005502314A JP2005502314A (ja) | 2005-01-27 |
| JP2005502314A5 true JP2005502314A5 (https=) | 2005-12-22 |
| JP4238031B2 JP4238031B2 (ja) | 2009-03-11 |
Family
ID=9909970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002570736A Expired - Fee Related JP4238031B2 (ja) | 2001-03-03 | 2002-03-01 | ワクチン |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20050260216A1 (https=) |
| EP (1) | EP1368477A1 (https=) |
| JP (1) | JP4238031B2 (https=) |
| KR (1) | KR20030081490A (https=) |
| CN (1) | CN1543504A (https=) |
| AU (1) | AU2002233560B2 (https=) |
| BR (1) | BR0207819A (https=) |
| CA (1) | CA2439628A1 (https=) |
| CZ (1) | CZ20032373A3 (https=) |
| GB (1) | GB0105360D0 (https=) |
| HU (1) | HUP0303372A3 (https=) |
| IL (1) | IL157498A0 (https=) |
| MX (1) | MXPA03007915A (https=) |
| NO (1) | NO20033882L (https=) |
| NZ (1) | NZ527873A (https=) |
| PL (1) | PL365066A1 (https=) |
| WO (1) | WO2002070711A1 (https=) |
| ZA (1) | ZA200306647B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ517929A (en) * | 1999-09-25 | 2004-02-27 | Univ Iowa Res Found | Immunostimulatory nucleic acids |
| US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| JP2006503017A (ja) * | 2002-08-30 | 2006-01-26 | グラクソ グループ リミテッド | Ｉｌ−１３要素及びｔ細胞エピトープを含む免疫原組成物並びにその治療上の使用 |
| WO2004019975A2 (en) * | 2002-08-30 | 2004-03-11 | Glaxo Group Limited | Il-14 vaccine for the treatment of asthma and atopic disorders |
| AU2003263150A1 (en) * | 2002-09-12 | 2004-04-30 | Pharmexa A/S | Immunization against autologous ghrelin |
| US9259459B2 (en) * | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
| ATE552860T1 (de) * | 2003-01-31 | 2012-04-15 | Celldex Res Corp | Antikörper-vakzine-konjugate und ihre verwendungen |
| JP2007525436A (ja) * | 2003-03-24 | 2007-09-06 | マーシア・ファーマ・インコーポレイテッド | 炎症症状を処置および予防するための方法および組成物 |
| WO2004096849A2 (en) * | 2003-04-25 | 2004-11-11 | University Of Manitoba | Peptide-based cytokine/chemokine vaccines against allergy |
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| EP1767216B1 (en) * | 2004-06-11 | 2012-07-11 | Riken | Drug having regulatory cell ligand contained in liposome |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| PL2068918T5 (pl) | 2006-09-26 | 2024-12-02 | Access To Advanced Health Institute | Kompozycja szczepionki zawierająca syntetyczny adiuwant |
| AR066240A1 (es) * | 2007-04-23 | 2009-08-05 | Wyeth Corp | Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13 |
| WO2008147956A2 (en) * | 2007-05-25 | 2008-12-04 | Centocor, Inc. | Toll-like receptor 3 modulators and uses thereof |
| CN101888856B (zh) | 2007-11-07 | 2014-08-27 | 塞尔德克斯医疗公司 | 结合人树突和上皮细胞205(dec-205)的抗体 |
| HRP20181102T1 (hr) | 2012-05-16 | 2018-09-07 | Immune Design Corp | Cjepiva za hsv-2 |
| MX370573B (es) | 2013-04-18 | 2019-12-17 | Immune Design Corp | Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer. |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| JP2024504194A (ja) * | 2021-01-29 | 2024-01-30 | エランコ アニマル ヘルス ゲー・エム・ベー・ハー | 自己寛容を破壊するためのワクチン組成物 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4866034A (en) * | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4945050A (en) * | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4877611A (en) * | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US5278302A (en) * | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5697901A (en) * | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
| AU661684B2 (en) * | 1991-06-18 | 1995-08-03 | Regents Of The University Of California, The | Cloned glutamic acid decarboxylase |
| DE4137333A1 (de) * | 1991-11-13 | 1993-05-19 | W Prof Dr Sebald | Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung |
| EP1167379A3 (en) * | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| HUT76369A (en) * | 1994-07-29 | 1997-08-28 | Smithkline Beecham Corp | Novel soluble protein compounds |
| US5696234A (en) * | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
| EP0815136B1 (en) * | 1995-02-20 | 2007-06-13 | The Walter And Eliza Hall Institute Of Medical Research | Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm) |
| US6518061B1 (en) * | 1995-03-15 | 2003-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| US5614191A (en) * | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| EP0759468A1 (en) * | 1995-08-10 | 1997-02-26 | Laboratoires Virbac | Feline interleukin-4 |
| US5666153A (en) * | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
| US6664227B1 (en) * | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| US5843449A (en) * | 1996-03-25 | 1998-12-01 | Akzo Nobel N.V. | Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases |
| US5856462A (en) * | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| ES2297889T3 (es) * | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
| EP0911401A1 (en) * | 1997-10-21 | 1999-04-28 | Bayer Ag | Muteins of interleukin 4 showing low-affinity and short-term interaction with the common gamma chain |
| JP2002506618A (ja) * | 1998-03-20 | 2002-03-05 | ジェンザイム・コーポレーション | 腫瘍自己抗原に対する免疫誘導 |
| US6576232B1 (en) * | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
| WO2000078334A1 (en) * | 1999-06-17 | 2000-12-28 | University Of Maryland Biotechnology Institute | Chimeric chemokine-antigen polypeptides and uses therefor |
| EP1263785A2 (en) * | 1999-11-11 | 2002-12-11 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mutated il-13 molecules and their uses |
-
2001
- 2001-03-03 GB GBGB0105360.2A patent/GB0105360D0/en not_active Ceased
-
2002
- 2002-03-01 CA CA002439628A patent/CA2439628A1/en not_active Abandoned
- 2002-03-01 JP JP2002570736A patent/JP4238031B2/ja not_active Expired - Fee Related
- 2002-03-01 EP EP02700490A patent/EP1368477A1/en not_active Withdrawn
- 2002-03-01 AU AU2002233560A patent/AU2002233560B2/en not_active Ceased
- 2002-03-01 NZ NZ527873A patent/NZ527873A/en unknown
- 2002-03-01 MX MXPA03007915A patent/MXPA03007915A/es not_active Application Discontinuation
- 2002-03-01 HU HU0303372A patent/HUP0303372A3/hu unknown
- 2002-03-01 CZ CZ20032373A patent/CZ20032373A3/cs unknown
- 2002-03-01 KR KR10-2003-7011573A patent/KR20030081490A/ko not_active Ceased
- 2002-03-01 BR BR0207819-8A patent/BR0207819A/pt not_active IP Right Cessation
- 2002-03-01 US US10/469,561 patent/US20050260216A1/en not_active Abandoned
- 2002-03-01 CN CNA028093240A patent/CN1543504A/zh active Pending
- 2002-03-01 PL PL02365066A patent/PL365066A1/xx unknown
- 2002-03-01 WO PCT/GB2002/000900 patent/WO2002070711A1/en not_active Ceased
- 2002-03-01 IL IL15749802A patent/IL157498A0/xx unknown
- 2002-09-03 US US10/233,902 patent/US20030194391A1/en not_active Abandoned
-
2003
- 2003-08-26 ZA ZA200306647A patent/ZA200306647B/en unknown
- 2003-09-02 NO NO20033882A patent/NO20033882L/no not_active Application Discontinuation
-
2005
- 2005-01-24 US US11/041,636 patent/US20050186209A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005502314A5 (https=) | ||
| JP4446601B2 (ja) | Ｂ群連鎖球菌の糖質を免疫学的に模倣する抗イディオタイプ抗体を含むワクチン処方物 | |
| EP2214840B1 (en) | Compositions and methods of enhancing immune responses to flagellated bacterium | |
| JP2018135355A (ja) | リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用 | |
| CN103180343B (zh) | 用于预防或治疗宫颈癌的、包含人乳头瘤病毒变形体及免疫增强剂的组合物 | |
| CN1073878A (zh) | 用病毒抗原表达特异性免疫原 | |
| JP2006504653A5 (https=) | ||
| JP2014500724A5 (https=) | ||
| JP2006500035A (ja) | ヘルペスウイルス科の核酸配列および／またはポリペプチド配列を含むワクチンの同定方法およびワクチン接種用組成物 | |
| JP5415399B2 (ja) | 核酸 | |
| CN101969990A (zh) | 增强针对艾美球虫属的免疫反应的组合物和方法 | |
| CN115850506B (zh) | 一种cd4辅助性t细胞表位融合肽及其疫苗 | |
| JP7824655B2 (ja) | Ｒｓｖワクチン組成物、方法、およびその使用 | |
| JP6057296B2 (ja) | Ｄｎａワクチン | |
| JP2006503017A5 (https=) | ||
| CN114634578A (zh) | 针对新型冠状病毒感染的疫苗组合物 | |
| EP1904626B1 (en) | Chimeric empty viral-like particles derived from the infectious bursal disease virus (ibdv), process for their production and applications | |
| JP2009501012A5 (https=) | ||
| JP2003520568A (ja) | 高度な抗原提示プラットフォーム | |
| CN109562157A (zh) | 多价重组spv | |
| Oli et al. | Vaccine types and reverse vaccinology | |
| CN115960185B (zh) | 一种c型鸡传染性鼻炎亚单位疫苗及其制备方法与应用 | |
| HU218102B (hu) | Rekombináns vakcinák Marek-féle betegség ellen | |
| CN114632148B (zh) | 病原样抗原疫苗及其制备方法 | |
| Talwar et al. | The impact of new technologies on vaccines |